Topical Corticosteroid-induced Skin Atrophy: a Comprehensive Review

Overview

Journal Drug Saf

Specialties Pharmacology
Toxicology

Date 2015 Apr 12

PMID 25862024

Citations 41

Authors

Laurent Barnes

Gurkan Kaya

Victoria Rollason

Affiliations

Soon will be listed here.

Abstract

Skin atrophy is an adverse effect of topical corticosteroids (TCs) which, as an established non-life-threatening effect, has been poorly reported by trials involving these drugs. Atopic dermatitis and psoriasis are example of disorders that require repeated therapies with TCs; however, assessing the atrophogenic activity of TCs is still an issue. This study aims to review clinical data on skin atrophy induced by TCs. Searches of the PubMed, EMBASE, and Cochrane (Central) databases from 1965 to May 2013 were undertaken using the keywords 'corticosteroid', 'skin', and 'atrophy'. Skin and epidermal thickness values were retrieved from trials on healthy skin, and studies including skin atrophy as a safety endpoint in trials testing the efficacy of TCs were analyzed. Overall, 60 articles were retrieved. Whole skin and epidermal thickness were relevant parameters to measure early skin atrophy on healthy skin before it becomes clinically obvious. Epidermis thickness also seems to be more sensitive than whole skin thickness in detecting early atrophy; however, measuring skin atrophy still requires standardization. Further clinical trials on the atrophic effects of each TC are required to better evaluate their respective atrophic risks and their risk/benefit ratios. However, measuring epidermal or whole skin thickness will not be relevant in acute phases of inflammatory skin disorders treated with TCs because of the thickening induced by inflammation. In addition, skin atrophy seems to be induced by chronic TC use rather than by acute treatments. Long-term safety studies may be more relevant to evaluate atrophic activity.

Citing Articles

Efficacy of Mild-to-Moderate Chronic Hand Eczema Treatment Using Petrolatum and Panthenol Ointment vs. 0.1% Triamcinolone Acetonide in 10% Urea Cream: A Split-hand, Evaluator-blinded, Randomized, Controlled Trial.

Lueangarun S, Techalert N, Tempark T J Clin Aesthet Dermatol. 2025; 18(2):38-43.

PMID: 40078865 PMC: 11896615.

HF-Ultrasonography to Quantify Skin Atrophy in Patients with Inflammatory Rheumatic Diseases Treated with Courses of Glucocorticoids.

Schuster A, Horn A, Gunther F, Fleck M, Hartung W, Ehrenstein B Diagnostics (Basel). 2025; 15(5).

PMID: 40075866 PMC: 11898456. DOI: 10.3390/diagnostics15050619.

Nano-Based Hydrogel for Cutaneous Sesamol Delivery in UVB-Induced Skin Injury.

Prado V, Moenke K, Pegoraro N, Saccol C, Nogueira-Librelotto D, Rechia G AAPS PharmSciTech. 2025; 26(3):75.

PMID: 40045094 DOI: 10.1208/s12249-025-03071-1.

A New Prescription Emollient Device (PED) For Psoriasis of Sensitive Areas and Folds: A Randomized Prospective Open Trial.

dallOglio F, Verzi A, Guglielmi G, Zappulla S, Micali G Psoriasis (Auckl). 2024; 14:135-142.

PMID: 39564575 PMC: 11575454. DOI: 10.2147/PTT.S465545.

Elongation of Very Long-Chain Fatty Acids (ELOVL) in Atopic Dermatitis and the Cutaneous Adverse Effect AGEP of Drugs.

Blaess M, Csuk R, Schatzl T, Deigner H Int J Mol Sci. 2024; 25(17).

PMID: 39273293 PMC: 11395647. DOI: 10.3390/ijms25179344.

References

Sorg O, Antille C, Kaya G, Saurat J . Retinoids in cosmeceuticals. Dermatol Ther. 2006; 19(5):289-96. DOI: 10.1111/j.1529-8019.2006.00086.x. View

Gans E, Sadiq I, Stoudemayer T, Stoudemayer M, Kligman A . In vivo determination of the skin atrophy potential of the super-high-potency topical corticosteroid fluocinonide 0.1% cream compared with clobetasol propionate 0.05% cream and foam, and a vehicle. J Drugs Dermatol. 2008; 7(1):28-32. View

Pariser D . Topical corticosteroids and topical calcineurin inhibitors in the treatment of atopic dermatitis: focus on percutaneous absorption. Am J Ther. 2009; 16(3):264-73. DOI: 10.1097/MJT.0b013e31818a975c. View

Lotti T, Buggiani G, Troiano M, Assad G, Delescluse J, De Giorgi V . Targeted and combination treatments for vitiligo. Comparative evaluation of different current modalities in 458 subjects. Dermatol Ther. 2008; 21 Suppl 1:S20-6. DOI: 10.1111/j.1529-8019.2008.00198.x. View

Kirkup M, Birchall N, Weinberg E, Helm K, Kennedy C . Acute and maintenance treatment of atopic dermatitis in children - two comparative studies with fluticasone propionate (0.05%) cream. J Dermatolog Treat. 2003; 14(3):141-8. DOI: 10.1080/09546630310013388. View

Maloney J, Morman M, Stewart D, Tharp M, Brown J, Rajagopalan R . Clobetasol propionate emollient 0.05% in the treatment of atopic dermatitis. Int J Dermatol. 1998; 37(2):142-4. DOI: 10.1046/j.1365-4362.1998.00394.x. View

Jarratt M, Clark S, Savin R, Swinyer L, Safley C, Brodell R . Evaluation of the efficacy and safety of clobetasol propionate spray in the treatment of plaque-type psoriasis. Cutis. 2006; 78(5):348-54. View

Snyder D, Greenberg R . Radiographic measurement of topical corticosteroid-induced atrophy. J Invest Dermatol. 1977; 69(3):279-81. DOI: 10.1111/1523-1747.ep12507493. View

Hengge U, Ruzicka T, Schwartz R, Cork M . Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2005; 54(1):1-15. DOI: 10.1016/j.jaad.2005.01.010. View

10.

Hoffmann K, Auer T, Stucker M, Hoffmann A, Altmeyer P . Comparison of skin atrophy and vasoconstriction due to mometasone furoate, methylprednisolone and hydrocortisone. J Eur Acad Dermatol Venereol. 1998; 10(2):137-42. View

11.

Tan M, Meador S, Singer G, Lebwohl M . An open-label study of the safety and efficacy of limited application of fluticasone propionate ointment, 0.005%, in patients with atopic dermatitis of the face and intertriginous areas. Int J Dermatol. 2002; 41(11):804-9. DOI: 10.1046/j.1365-4362.2002.01571.x. View

12.

Kragballe K, Hoffmann V, Ortonne J, Tan J, Nordin P, Segaert S . Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial. Br J Dermatol. 2009; 161(1):159-66. DOI: 10.1111/j.1365-2133.2009.09116.x. View

13.

Kwon H, Choi Y, Kim H, Lee A . The therapeutic effects of a topical tretinoin and corticosteroid combination for vitiligo: a placebo-controlled, paired-comparison, left-right study. J Drugs Dermatol. 2013; 12(4):e63-7. View

14.

Schmied C, Piletta P, Saurat J . Treatment of eczema with a mixture of triamcinolone acetonide and retinoic acid: a double-blind study. Dermatology. 1993; 187(4):263-7. DOI: 10.1159/000247260. View

15.

Theng C, Tan S, Goh C, Suresh S, Wong H, Machin D . A randomized controlled trial to compare calcipotriol with betamethasone valerate for the treatment of cutaneous lichen planus. J Dermatolog Treat. 2004; 15(3):141-5. DOI: 10.1080/09546630410031891. View

16.

van der Vleuten C, de Jong E, van de Kerkhof P . Clobetasol-17 propionate lotion under hydrocolloid dressing (Duoderm ET) once weekly versus unoccluded clobetasol-17-propionate ointment twice daily in psoriasis: an immunohistochemical study on remission and relapse. Arch Dermatol Res. 1999; 291(7-8):390-5. DOI: 10.1007/s004030050427. View

17.

Kaidbey K, Kopper S, Sefton J, Gibson J . A pilot study to determine the effect of tazarotene gel 0.1% on steroid-induced epidermal atrophy. Int J Dermatol. 2001; 40(7):468-71. DOI: 10.1046/j.1365-4362.2001.01234.x. View

18.

Feldman S, Koo J, Johnson L, Preston N . Clobetasol propionate spray 0.05% add-on therapy to a stable regimen of biologic treatment in patients with moderate to very severe plaque psoriasis. Cutis. 2009; 84(4 Suppl):25-32. View

19.

McMichael A, Griffiths C, Talwar H, Finkel L, Rafal E, Hamilton T . Concurrent application of tretinoin (retinoic acid) partially protects against corticosteroid-induced epidermal atrophy. Br J Dermatol. 1996; 135(1):60-4. View

20.

HERZ G, Yawalkar S, WEIRICH E . Evaluation of halometasone ointment in the treatment of paediatric patients with chronic eczematous dermatoses. J Int Med Res. 1983; 11 Suppl 1:21-5. View